Theriva Biologics
Theriva™ Biologics is a clinical-stage immuno-oncology company developing oncolytic viruses to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Their therapies aim to enable systemic delivery and enhance current standard-of-care treatments, offering hope for patients with difficult-to-treat cancers. The company is driven by experienced leaders and a mission to change the cancer therapy landscape.
Industries
Nr. of Employees
small (1-50)
Theriva Biologics
Rockville, Maryland, United States, North America
Products
Pipeline of clinical-stage systemically deliverable oncolytic virus candidates
A portfolio of oncolytic viral therapy candidates engineered for systemic administration and selective tumor destruction, under clinical evaluation for multiple solid tumor indications.
Pipeline of clinical-stage systemically deliverable oncolytic virus candidates
A portfolio of oncolytic viral therapy candidates engineered for systemic administration and selective tumor destruction, under clinical evaluation for multiple solid tumor indications.
Services
Expanded access policy and procedures
Maintains an expanded access policy to facilitate patient requests and describe procedures for potential access to investigational therapies.
Scientific presentations and data dissemination
Preparation and delivery of clinical and scientific presentations at industry conferences and investigator meetings; hosting webcasts and conference calls for data disclosure.
Expanded access policy and procedures
Maintains an expanded access policy to facilitate patient requests and describe procedures for potential access to investigational therapies.
Scientific presentations and data dissemination
Preparation and delivery of clinical and scientific presentations at industry conferences and investigator meetings; hosting webcasts and conference calls for data disclosure.
Expertise Areas
- Oncolytic virotherapy development
- Viral vector (adenovirus) engineering
- Immuno-oncology translational research
- Clinical trial management (Phase I–IIb)
Key Technologies
- Oncolytic virotherapy
- Adenovirus-based viral vectors
- Systemic delivery of viral therapeutics
- Immuno-oncology therapeutic approaches